Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Cancer and Leukemia Group B National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00061945 |
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as alemtuzumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of alemtuzumab and to see how well it works when given together with combination chemotherapy in patients with previously untreated acute lymphoblastic leukemia.
Condition | Intervention | Phase |
---|---|---|
Leukemia |
Biological: alemtuzumab Biological: filgrastim Drug: asparaginase Drug: cyclophosphamide Drug: cytarabine Drug: daunorubicin hydrochloride Drug: dexamethasone Drug: imatinib mesylate Drug: leucovorin calcium Drug: mercaptopurine Drug: methotrexate Drug: vincristine sulfate |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL) |
Estimated Enrollment: | 282 |
Study Start Date: | June 2003 |
Estimated Primary Completion Date: | October 2005 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: This is a multicenter, dose-escalation study of alemtuzumab. All courses are 28 days in length except courses 3 and 7 which are 42 days.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Course 3 (CNS prophylaxis): After sufficient recovery from course 2, patients receive vincristine IV over 1-2 minutes, methotrexate IV over 3 hours, and methotrexate IT on days 1, 15, and 29; oral methotrexate every 6 hours for 4 doses beginning 6 hours after the start of methotrexate IV infusion on days 1, 15, and 29; oral mercaptopurine on days 1-35; leucovorin calcium IV over 5-10 minutes on days 2, 16, and 30; and oral leucovorin calcium every 6 hours for 8 doses beginning 12 hours after IV leucovorin calcium on days 3 and 4, 17 and 18, and 31 and 32. Patients with Ph-positive disease also receive oral imatinib mesylate once daily on days 1-42. Patients who have CD52^+ disease as determined by pretreatment immunohistochemistry, and meet all of the following criteria proceed to course 4.
Course 4 (immunotherapy):
Patients receive oral mercaptopurine daily; vincristine IV over 1-2 minutes on day 1; oral methotrexate once weekly on days 1, 8, 15, and 22; and oral dexamethasone on days 1-5. Courses repeat every 28 days for up to 24 months from study entry. Patients with Ph-positive disease also receive oral imatinib mesylate once daily beginning on day 1 and continuing until completion of study therapy.
For testicular disease at study entry that persists or worsens after 4 weeks of therapy or testicular disease that develops after study therapy has begun, patients undergo testicular radiotherapy once daily 5 days a week for 13 treatments.
Patients with CNS leukemia receive methotrexate IT 1-2 times weekly for 5 weeks and leucovorin calcium IV 24 hours after each methotrexate dose.
Patients also undergo cranial radiotherapy once daily 5 days a week for 12 treatments. Radiotherapy begins on day 5 of course 1 for patients with CNS leukemia at study entry or the day after diagnosis of CNS leukemia for patients who develop disease after study therapy has begun. If remission is achieved, patients continue study therapy and receive methotrexate once monthly for 12 months.
Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually for up to 10 years from study entry.
PROJECTED ACCRUAL: A total of 18-36 patients will be accrued for the phase I portion of the study within 5-12 months (closed to accrual as of 7/5/2005).
A total of 236-282 patients will be accrued for the phase II portion of the study within 33-42 months.
Ages Eligible for Study: | 15 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
No prior treatment for leukemia except for any of the following:
Must have a pretreatment bone marrow or peripheral blood sample submitted for central immunophenotyping
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
No concurrent palliative radiotherapy
Surgery
Other
Study Chair: | Wendy Stock, MD | University of Chicago |
Study ID Numbers: | CDR0000302482, CALGB-10102 |
Study First Received: | June 5, 2003 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00061945 History of Changes |
Health Authority: | United States: Food and Drug Administration |
B-cell adult acute lymphoblastic leukemia L1 adult acute lymphoblastic leukemia L2 adult acute lymphoblastic leukemia |
T-cell adult acute lymphoblastic leukemia untreated adult acute lymphoblastic leukemia acute undifferentiated leukemia |
Dexamethasone Anti-Inflammatory Agents Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics 6-Mercaptopurine Hormones Protein Kinase Inhibitors Alemtuzumab Methotrexate Asparaginase Precursor Cell Lymphoblastic Leukemia-Lymphoma Immunoproliferative Disorders Antineoplastic Agents, Hormonal Vincristine |
Glucocorticoids Imatinib Folic Acid Antineoplastic Agents, Phytogenic Antimetabolites Daunorubicin Leukemia, Lymphoid Immunologic Factors Leucovorin Folate Cyclophosphamide Vitamin B9 Leukemia Anti-Bacterial Agents Vitamins |
Dexamethasone Anti-Inflammatory Agents Anti-Infective Agents Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics 6-Mercaptopurine Protein Kinase Inhibitors Hormones Alemtuzumab Therapeutic Uses Abortifacient Agents Methotrexate |
Dermatologic Agents Nucleic Acid Synthesis Inhibitors Asparaginase Precursor Cell Lymphoblastic Leukemia-Lymphoma Immunoproliferative Disorders Immune System Diseases Antineoplastic Agents, Hormonal Vincristine Abortifacient Agents, Nonsteroidal Glucocorticoids Imatinib Neoplasms Antineoplastic Agents, Phytogenic Antimetabolites Daunorubicin |